RecruitingInterventionalPhase 3Last updated Aug 14, 2026

A Study to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

A Randomized, Double-Blind, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

Overview

ClinicalTrials.gov ID: NCT07766655
Lead Sponsor: Axsome Therapeutics, Inc.INDUSTRY
Brief Summary: This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trial to evaluate the efficacy and safety of AXS-05 compared to placebo and bupropion for smoking cessation in adults.
Study Type: Interventional

Status

Study Record Dates

NCT03471767Completed

AXS-05 Phase II Trial on Smoking Behavior

NCT06223880Recruiting

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

NCT00176449Completed

A Comparison of Bupropion SR and Placebo for Smoking Cessation

NCT04868253Unknown status

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

NCT01312909Completed

Smoking Cessation Study In Healthy Adolescent Smokers

NCT04933916Terminated

Study of EMB-001 as a Potential Smoking Cessation Treatment